Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.
In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.
The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.
- Headquartered in Madison, Wisconsin
- Specializes in cancer screening and diagnostic tests
- Flagship product: Cologuard, a noninvasive colorectal cancer screening test
- Precision oncology products: Oncotype DX and OncoExTra
- Active development of liquid biopsy tests
- Exclusive intellectual property rights protecting screening technology
For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.
Exact Sciences Corp. (NASDAQ: EXAS) announced a collaboration with the West German Study Group (WSG) to conduct a multicenter validation study on minimal residual disease (MRD) in hormone receptor-positive, HER2-negative early breast cancer patients. The ADAPT Triad study aims to utilize Exact Sciences' ctDNA liquid biopsy test for detecting MRD, involving data from about 3,000 patients. This initiative supports Exact Sciences' goal to develop clinically validated MRD tests, enhancing treatment decisions and patient outcomes.
Exact Sciences Corp. (EXAS) announced its upcoming participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10, 2022, at 4:00 p.m. ET. The event will include a fireside chat, inviting investors to join via webcast. Exact Sciences, recognized for its innovative cancer screening and diagnostic tests, continues to seek advanced solutions for early cancer detection and treatment. The webcast will be accessible through their investor relations section at www.exactsciences.com.
Exact Sciences Corp. (NASDAQ: EXAS) applauds the CMS proposal to classify follow-up colonoscopy after positive at-home colorectal cancer tests as a preventive service, eliminating costs for Medicare patients. The proposal extends coverage to individuals aged 45 and older and aligns with recommendations from the USPSTF and the American Cancer Society. With 44 million unscreened average-risk adults in the U.S., this change aims to increase access to cancer screening and early detection. The final rule is expected to be published in fall 2022 and take effect on January 1, 2023.
Exact Sciences Corp. (Nasdaq: EXAS) announced it will release its second quarter 2022 financial results after the U.S. markets close on August 2, 2022. Following the announcement, management will host a webcast and conference call at 5 p.m. ET to discuss the results and business progress. The call is accessible via telephone and will also be available as a recorded archive on their website. Exact Sciences focuses on cancer screening and diagnostic tests, notably with products like Cologuard and Oncotype.
Exact Sciences and Ultima Genomics have established a long-term supply agreement to utilize Ultima's innovative next-generation sequencing (NGS) technologies, promising to reduce sequencing costs dramatically. This collaboration aims to enhance cancer diagnostic tests and expand patient access to genomic-based testing. With Exact Sciences investing in Ultima and participating in the early access program for the UG 100™ high-throughput NGS instrument, both companies anticipate substantial advancements in genomic information and improved patient outcomes across cancer treatment stages.
Exact Sciences Corp. (NASDAQ: EXAS) announced the presentation of new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. The company will showcase findings from nine poster presentations and five e-abstracts, focusing on cancer diagnostics and treatment solutions. Critical studies include comparisons between stool- and blood-based colorectal cancer screening tests and the use of methylated DNA markers for various cancers. Kevin Conroy, CEO, emphasized the need for innovative cancer detection methods to improve patient outcomes.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in June 2022. Key events include:
- William Blair 42nd Annual Growth Stock Conference on June 6, 2022, at 3:40 p.m. ET in Chicago.
- Jefferies Healthcare Conference on June 8, 2022, at 1:00 p.m. ET in New York.
- Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 6:20 p.m. ET in Rancho Palos Verdes.
- Nephron Liquid Biopsy Innovation Symposium on June 21, 2022, at 11:00 a.m. ET (virtual).
Exact Sciences Corp. (NASDAQ: EXAS) announced participation in the BofA Securities Healthcare Conference in Las Vegas on May 11, 2022, at 5:00 p.m. ET. Investors can access the webcast via the investor relations section of Exact Sciences' website. The company is focused on cancer diagnostics, developing tests like Cologuard and Oncotype to support patients throughout their cancer journey. Exact Sciences aims to provide innovative solutions for cancer screening and diagnosis.
Exact Sciences Corp. (NASDAQ: EXAS) announced that its Oncotype DX Breast Recurrence Score test has received the highest rating in the American Society of Clinical Oncology (ASCO) guidelines for quality of evidence. The updated guidelines expand the test's use for early-stage breast cancer patients, especially in postmenopausal women with positive lymph nodes and premenopausal patients with node-negative disease. The RxPONDER study, published in The New England Journal of Medicine, underpins this recommendation, indicating significant data supporting tailored chemotherapy decisions.
Exact Sciences Corp. (NASDAQ: EXAS) reported a 21% increase in total revenue for Q1 2022, reaching $486.6 million, compared to $402.1 million in Q1 2021. Excluding COVID-19 testing, revenue grew 24%, driven by a 28% increase in Screening revenue to $306.5 million and an 18% rise in Precision Oncology revenue to $152.6 million. Despite this growth, the company faced a net loss of $180.9 million or $1.04 per share.
The 2022 revenue outlook is raised to $1,985-$2,032 million, bolstered by strong Screening and Precision Oncology performance.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
What is Exact Sciences Corp's main business?
What is Cologuard?
Where is Exact Sciences Corp headquartered?
What are Oncotype DX and OncoExTra?
Is Exact Sciences developing any new tests?
What is the significance of Exact Sciences' intellectual property?
Are Exact Sciences' products used internationally?
How does Cologuard work?
What is the purpose of Oncotype DX tests?
Where can more information about Cologuard be found?
